Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
Melbourne (Australia) and Athens (Greece) – 28 January 2022. Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot markets.
Telix is pleased to announce that it has entered into an exclusive commercial distribution agreement with Athens-based BIOKOSMOS S.A. (BIOKOSMOS) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Greek and Cypriot markets.
Under the terms of the agreement, BIOKOSMOS will be the overall distributor and local representative for Illuccix in Greece and Cyprus for a period of three years. BIOKOSMOS is a key radiopharmaceutical manufacturer in Greece and has built a comprehensive distribution network, which covers the full Greek Territory as well as Cyprus and the wider Balkan region.
BIOKOSMOS CEO, Angelos Pagonis stated, “It is a great pleasure to have signed this distribution agreement with Telix, which subject to regulatory approval, will help facilitate widespread access to gallium-based PSMA-PET imaging for Greek and Cypriot men in need. Already included in latest European and U.S. clinical practice guidelines, we are excited by the opportunity to help bring this state-of-the-art imaging modality to market in Europe, with potential to enhance patient outcomes.”
Telix EMEA President Richard Valeix added, “As Telix’s European marketing authorisation application continues to progress, we are pleased to have added this important commercial distribution agreement with BIOKOSMOS for the Greek and Cypriot markets. Partnering with such an established and capable leader in Greek nuclear medicine aligns with Telix’s purpose to help people with cancer and rare diseases live longer, better quality lives.”
To read the full media release please click here.
To return to Telix’s home page please click here.